Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment
ConclusionsEBR/GZR represents an important treatment option for HCV infection in people with severe renal impairment and those with ESRD. No dosage adjustment of EBR/GZR is required in people with any degree of renal impairment, including those receiving dialysis.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Kidney Disease | Dialysis | Drugs & Pharmacology | Hemodialysis | Hepatitis | Hepatitis C | Study | Urology & Nephrology